Calling this number connects you with a Patient Advocate at The Mesothelioma Center, the nation's most trusted mesothelioma resource.
Our Patient Advocates can help guide you or your loved one through the steps to take after a mesothelioma diagnosis. Our team has a combined experience of more than 30 years in assisting cancer patients, and includes a medical doctor, an oncology registered nurse and a U.S. Navy veteran.
Tumor Treating Fields, also known as TTFields, is a new cancer therapy approved by the U.S. Food and Drug Administration to treat pleural mesothelioma. It works in combination with chemotherapy to limit cancer growth and improve survival.
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Reviewed
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
Assisting mesothelioma patients and their loved ones since 2006.
Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
A+ rating from the Better Business Bureau.
5-star reviewed mesothelioma and support organization.
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."
Selby, K. (2023, January 9). Tumor Treating Fields (TTFields) and Mesothelioma. Asbestos.com. Retrieved January 31, 2023, from https://www.asbestos.com/treatment/ttfields/
MLA
Selby, Karen. "Tumor Treating Fields (TTFields) and Mesothelioma." Asbestos.com, 9 Jan 2023, https://www.asbestos.com/treatment/ttfields/.
Chicago
Selby, Karen. "Tumor Treating Fields (TTFields) and Mesothelioma." Asbestos.com. Last modified January 9, 2023. https://www.asbestos.com/treatment/ttfields/.
How Is Tumor Treating Fields Used to Treat Mesothelioma?
Tumor Treating Fields is a new type of anti-cancer therapy that uses alternating electrical fields to limit cancer growth. It is combined with chemotherapy to control the growth of pleural mesothelioma.
In May 2019, TTFields became the second pleural mesothelioma treatment to be approved by the U.S. Food and Drug Administration.
The first mesothelioma treatment approved by the FDA was a chemotherapy regimen combining Alimta (pemetrexed) with cisplatin or carboplatin, which was approved in 2004. TTFields is administered in combination with this chemotherapy regimen.
A company called Novocure invented the noninvasive technology and has been developing Tumor Treating Fields since 2000. TTFields received its first approval from the FDA in 2011 to treat a type of brain cancer called glioblastoma.
The clinical trial that led the FDA to approve TTFields for pleural mesothelioma reported an overall survival of 18.2 months.
Patients in the trial who received only chemotherapy lived 12.1 months. The addition of TTFields helped patients live an average of six months longer.
TTFields doesn’t offer a cure for mesothelioma, but it can significantly improve survival with a low risk of side effects.
Tumor Treating Fields is a novel therapy different from chemotherapy or radiation therapy. Basically, low-voltage electrical fields are safely applied through the skin to disrupt the microelectrical currents inside cells required for their division. It ‘jams up’ those fields inside tumor cells, not allowing them to divide, multiply or grow.
Dr. Jacques Fontaine
Thoracic Surgeon for Mesothelioma
How Does TTFields Work?
Tumor Treating Fields applies alternating electrical fields of an intermediate frequency that are low in intensity.
The electrical fields are delivered through insulated pads that adhere to skin. The electrical field frequency is 100 to 300 kilohertz, and the intensity is delivered at 1 to 3 volts per centimeter.
Research shows that applying this range of alternating frequencies to cancer cells has the power to disrupt certain proteins that are essential to cell division.
When the electrical fields enter a cancer cell, they prevent these proteins from functioning properly. This stops cancer cells from multiplying, which limits tumor growth and may kill some cancer cells.
A a 2021 study published in Lung Cancer helps further explain why TTFields improves chemotherapy results. Researchers disovered the addition of TTFields to chemotherapy increases the expression of proteins that damage cancer DNA and reduces the level of proteins that repair cancer DNA. Damaged cancer DNA leads to tumor cell death.
Find a Mesothelioma Cancer Center
Access top mesothelioma cancer centers that have experience treating this rare disease.
Novocure’s TTFields delivery system for mesothelioma, branded under the name Optune Lua (previously known as the NovoTTF-100L System), is a portable device that can be used anywhere.
The system comes with a TTFields-generating device, battery charger and rechargeable batteries, power supply, insulated pads and a carrying bag.
The components of Novocure’s NovoTTF-100L Tumor Treating Fields System, which is now approved as a first-line treatment for malignant pleural mesothelioma.
The treatment is designed for continual use at home or on-the-go. The carrying bag can be worn as a backpack or held in your hand.
The therapy is applied with four pads attached to the front and back of a patient’s chest. The pads are changed every two to three days, and the area must be shaved. It involves no skin incisions or insertion of any medical devices into the body.
Patients are advised to wear NovoTTF-100L for 18 to 20 hours a day until their cancer progresses.
Patients can carry on with their lives while receiving treatment. They can run errands, take walks and do house chores while the therapy is administered.
However, keeping the device charged may present some logistical challenges for active people. NovoTTF-100L is plugged into a power supply or uses a large rechargeable battery pack that must be carried to power the device.
Every three weeks, patients will receive chemotherapy with Alimta and cisplatin or carboplatin for six cycles. Research shows that using NovoTTF-100L does not increase the toxicity of chemotherapy.
NovoTTF-100L is only prescribed with chemotherapy. That means patients must take chemotherapy to use the device.
Side Effects of TTFields for Mesothelioma
The most common side effects of TTFields plus chemotherapy in pleural mesothelioma patients include:
Skin irritation is reported in nearly half of patients who receive the therapy, but only 4% of patients report a severe level of irritation.
Contraindications, Warnings and Precautions
Do not use TTFields if:
You have an active implanted medical device such as a pacemaker
You have a sensitivity to conductive hydrogels (severe allergic reactions are possible)
You are pregnant or trying to get pregnant
The NovoTTF-100L System can only be prescribed by a mesothelioma doctor that has completed required certification training.
Patients with an underlying serious skin condition on the chest may not be able to receive Novocure’s mesothelioma treatment.
Research on Mesothelioma and TTFields
The clinical trial that led the FDA to approve NovoTTF-100L for pleural mesothelioma reported the following:
Patients lived an average of six months longer with the addition of NovoTTF-100L (18.2 months) compared to those only receiving chemotherapy (12.1 months).
More than 97% of patients responded to the therapy with tumor shrinkage or no new tumor growth.
Patients with epithelial mesothelioma, which responds best to treatment, lived 21.2 months.
Participants using NovoTTF-100L had no new cancer growth for an average of 7.6 months. Those only receiving chemotherapy had no new cancer growth for 5.7 months.
Immunotherapy is quickly becoming an essential treatment option for many mesothelioma patients. While it may not yet be an effective therapy for every…
In October 2019, a patient at West Cancer Center in Memphis, Tennessee, became the first pleural mesothelioma patient outside of a clinical trial to use NovoTTF-100L since it was approved by the FDA.
Since February 2020, over 40 cancer centers across the U.S. have become certified to prescribe TTFields to patients with pleural mesothelioma. Many more centers are also seeking approval to offer the device.
“We are always looking for treatments to improve the survival, quality of life and options for patients,” said thoracic surgeon Dr. Taylor Ripley, director of the Mesothelioma Treatment Center at Baylor College of Medicine. “This provides another therapeutic option that may be valuable.”
Treatment Centers Certified for Tumor Treating Fields
Treatment Center
doctors
Allegheny General Hospital
Dr. Zachary Horne Dr. Tom Colonias
Baylor College of Medicine
Dr. Pavan Jhaveri
Beaumont Hospital
Dr. Craig Stevens Dr. Zachary Seymour
Cleveland Clinic
Dr. Gregory Videtic
Frye Regional Medical Center
Dr. John O. DelCharco
Loyola University Medical Center
Dr. Tamer Abdelrhman Dr. Raymond Wynn
Miami Cancer Institute
Dr. Rupesh Kotecha
Ochsner Medical Center
Dr. Rockne Hymel Dr. Clayton Smith
Oregon Health and Science University
Dr. John Holland Dr. Josh Walker
Sylvester Comprehensive Cancer Center
Dr. Alan Dal Pra Dr. Derek Isrow
West Cancer Clinic
Dr. Matthew Ballo Dr. Cilla Edmonston Dr. Wes Garner Dr. Yuefeng Wang
Novocure’s other TTFields device, called Optune, is specially designed to treat glioblastoma. It cannot be used to treat mesothelioma.
If you are interested in TTFields, ask your doctor if they are certified to prescribe the NovoTTF-100L System, and ask if you qualify for the therapy. The FDA has approved it only for pleural mesothelioma patients with inoperable tumors.
Our free mesothelioma guide contains information on symptoms, top doctors, support resources and more. Get information tailored to your unique diagnosis, and learn about our free services.
Request Your Free Guide Today
Request a Text From a Patient Advocate
Your web browser is no longer supported by Microsoft. Update your browser for more security, speed and compatibility.
If you are looking for mesothelioma support, please contact our Patient Advocates at (855) 404-4592
